Table 2.

Change in BCVA study eye (SE) entire cohort, and categorisation by whether SE is ‘better’ or ‘worse’ relative to fellow eye in terms of letters at baseline*

	N included	Mean 1	Mean 2	Mean difference	95% CI	P value
All study eyes
Change baseline—M12	100	63.2	68.1	4.9	2.9 to 7.0	<0.001
Change baseline—M18	104	62.9	69.6	6.7	4.4 to 9.1	<0.001
Study eye is ‘better’ eye
Change baseline—M12	30	64.8	68.5	3.7	1.4 to 6.0	0.002
Change baseline—M18	32	65.1	68.2	3.1	−0.8 to 7.1	0.118
Study eye is ‘worse’ eye
Change baseline—M12	70	62.5	68.0	5.4	2.6 to 8.2	<0.001
Change baseline—M18	72	62.0	70.1	8.3	5.5 to 11.2	<0.001

*RELIGHT protocol stated that if both eyes are eligible, the one with the worse visual acuity, as assessed at visit 1, will be selected for study treatment unless, based on medical reasons, the investigator deems the other eye the more appropriate candidate for study treatment.

BCVA, best-corrected visual acuity.